253 results on '"Gabdoulline, Razif"'
Search Results
2. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
3. IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis
4. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
5. Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up
6. Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow
7. Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia
8. Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
9. MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
10. P1278: MEASURABLE RESIDUAL DISEASE ASSESSMENT IN THE PROSPECTIVE HAPLOMUD STUDY
11. P510: PREDICTORS OF RESPONSE AND OUTCOME IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA RECEIVING VENETOCLAX WITH NON-INTENSIVE CHEMOTHERAPY
12. Increased Late Noncardiac Nonrelapse Mortality in Patients with Atrial Fibrillation Diagnosed During Their Hospital Stay for Allogeneic Stem Cell Transplantation
13. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
14. Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia
15. Correction: Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia
16. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF
17. Electrostatic Steering and Ionic Tethering in Enzyme-Ligand Binding: Insights from Simulations
18. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation
19. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
20. DEK-NUP214 Acute Myeloid Leukemia Depends on CRM1 In Vivo
21. Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients
22. Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
23. Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation
24. Molecular Response Patterns in Relapsed/Refractory AML Patients Treated with Selinexor and Chemotherapy
25. Impact ofPPM1Dmutations in patients with myelodysplastic syndrome and deletion of chromosome 5q
26. The acidic, glutamine-rich Mpn474 protein of Mycoplasma pneumoniae is surface exposed and covers the complete cell
27. IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML
28. Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow
29. Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia
30. IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis
31. Kinetics of Biomacromolecular Complex Formation: Theory and Experiment
32. Computational Simulations of Protein– Protein and Protein– Nucleic Acid Association
33. Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up
34. Post Transplantation Measurable Residual Disease (MRD) Monitoring Using Next-Generation Sequencing Is Highly Predictive for Relapseafter Allogeneic Stem Cell Transplantation
35. Hematologic Recovery from Venetoclax-Containing Regimens in Relapsed/Refractory Acute Myeloid Leukemia Patients Depending on Prior Allogeneic Hematopoietic Cell Transplantation
36. FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia
37. Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia
38. Classification of auxin plant hormones by interaction property similarity indices
39. webPIPSA: a web server for the comparison of protein interaction properties
40. SYCAMORE—a systems biology computational analysis and modeling research environment
41. Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.
42. ProSAT: functional annotation of protein 3D structures
43. MolSurfer: a macromolecular interface navigator
44. Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia
45. Functional Screening for Pathways Regulating Chemoresistance and Sensitivity in Leukemia Stem Cells
46. Frequency and Clinical Characteristics Associated with Putative CAR Targets ADGRE2, CCR1, CD70, and LILRB2 in Acute Myeloid Leukemia
47. The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q
48. qPIPSA: Relating enzymatic kinetic parameters and interaction fields
49. IDH1/2mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis
50. Molsurfer: two-dimensional maps for navigating three-dimensional structures of proteins
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.